Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/4439
A61K-009/20
A61K-033/10
A61K-009/00
A61K-047/02
A61K-009/28
A61K-009/48
A61K-009/50
A61K-033/00
A61K-033/06
A61K-045/06
출원번호
US-0338608
(2006-01-24)
등록번호
US-8993599
(2015-03-31)
발명자
/ 주소
Hall, Warren
Olmstead, Kay
Weston, Laura
출원인 / 주소
Santarus, Inc.
대리인 / 주소
Novak Druce Connolly Bove + Quigg LLP
인용정보
피인용 횟수 :
1인용 특허 :
139
초록▼
In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the p
In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a taste-masking material and one or more antacid are described.
대표청구항▼
1. A solid pharmaceutical composition having an enhanced shelf-life, comprising: (a) about 1 to about 120 mg of omeprazole, or a free base, free acid, salt, enantiomer, isomer, or tautomer, thereof, in combination with sodium bicarbonate, wherein said combination is microencapsulated with a material
1. A solid pharmaceutical composition having an enhanced shelf-life, comprising: (a) about 1 to about 120 mg of omeprazole, or a free base, free acid, salt, enantiomer, isomer, or tautomer, thereof, in combination with sodium bicarbonate, wherein said combination is microencapsulated with a material that enhances the shelf-life of the pharmaceutical composition comprising at least one cellulose hydroxypropyl ether; and(b) about 1 to about 160 mEq of antacid comprising sodium bicarbonate wherein the pharmaceutical composition is not enteric coated and has less than 5% total new impurities after 1 year of storage at room temperature. 2. The pharmaceutical composition according to claim 1, wherein the antacid comprises at least one soluble buffer. 3. The pharmaceutical composition according to claim 2, wherein the soluble buffer is present in about 5 mEq to about 40 mEq. 4. The pharmaceutical composition according to claim 1 comprising about 500 to about 2000 mg of antacid. 5. The pharmaceutical composition according to claim 1, wherein the omeprazole has less than 1% degradation after one month of storage at room temperature. 6. The pharmaceutical composition according to claim 1 further comprising one or more excipients selected from the group consisting of parietal cell activators, organic solvents, erosion facilitators, flavoring agents, sweetening agents, diffusion facilitators, antioxidants and carrier materials selected from binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, diluents, anti-adherents, and antifoaming agents. 7. The pharmaceutical composition according to claim 6, wherein the flavoring agent comprises peach, menthol, aspartame, sucralose, xylitol, mint, sucrose, or a mixture thereof. 8. The pharmaceutical composition according to claim 1 in the form of a capsule, a chewable tablet, a tablet, or a powder. 9. The pharmaceutical composition according to claim 1, wherein the maximum serum concentration is reached within about 1 hour after administration of the pharmaceutical formulation to a subject. 10. The pharmaceutical composition according the claim 1, wherein the average particle size of the microencapsulated omeprazole is between about 20 to about 500 microns in diameter. 11. The pharmaceutical composition according the claim 1, wherein the average particle size of the microencapsulated proton pump inhibitor is between about 50 to about 150 microns in diameter. 12. A method of treating an acid related gastrointestinal disorder in a subject in need thereof by administering a pharmaceutical composition having an enhanced shelf-life, comprising: (a) about 1 to about 120 mg of omeprazole or a free base, free acid, salt, enantiomer, isomer, or tautomer thereof in combination with sodium bicarbonate, wherein said combination is microencapsulated with a material that enhances the shelf-life of the pharmaceutical composition wherein the material that enhances the shelf-life of the pharmaceutical formulation comprising at least one cellulose hydroxypropyl ether; and(b) about 1 to about 160 mEq of at least one antacid comprising sodium bicarbonate; wherein the pharmaceutical composition is not enteric coated and has less than 5% total new impurities after 1 year of storage at room temperature. 13. The pharmaceutical composition according to claim 1, wherein a serum concentration of the omeprazole is about 0.3 μg/ml within about 45 minutes after administration of the pharmaceutical formulation to a subject. 14. The pharmaceutical composition according to claim 1, wherein a serum concentration of the omeprazole is about 0.45μg/ml within about 30 minutes after administration of the pharmaceutical formulation to a subject. 15. The pharmaceutical composition according to claim 1, wherein a serum concentration of the omeprazole is about 0.1 μg/ml within about 15 minutes after administration of the pharmaceutical formulation to a subject. 16. The pharmaceutical composition according to claim 1, wherein about 50% of the omeprazole is released from the composition within about 1 hour after exposure to gastrointestinal fluid. 17. The pharmaceutical composition according to claim 1, wherein about 70% of the omeprazole is released from the composition within about 1.5 hours after exposure to gastrointestinal fluid. 18. The pharmaceutical composition according to claim 1, wherein a maximum serum concentration is reached within about 45 minutes after administration of the pharmaceutical formulation to a fasting subject. 19. The pharmaceutical composition according to claim 1, wherein the antacid is present in an amount of about 1 mEq to about 3 mEq per mg of omeprazole. 20. The pharmaceutical composition according to claim 1, wherein the antacid is present in an amount of between about 5 mEq to about 60 mEq. 21. The pharmaceutical composition according to claim 1, wherein the material that enhances the shelf-life of the pharmaceutical formulation sufficiently dissolves in water in less than about 30 minutes. 22. The pharmaceutical composition according to claim 1, wherein the material that enhances the shelf-life of the pharmaceutical formulation sufficiently disintegrates to release the omeprazole into the gastrointestinal fluid within about 1 hour. 23. The pharmaceutical composition according to claim 1, wherein the drug loading of the omeprazole into microspheres is about 20 wt-% of omeprazole to microencapsulated omeprazole. 24. The pharmaceutical composition according to claim 1, wherein the drug loading of the omeprazole into microspheres is between about 10 wt-% to about 60 wt-% of omeprazole to microencapsulated omeprazole. 25. A chewable tablet, comprising: (a) between about 1 to about 120 mg of omeprazole, or a free base, free acid, salt, enantiomer, isomer, or tautomer thereof in combination with sodium bicarbonate, wherein said combination is microencapsulated with a material that enhances the shelf-life of the chewable tablet comprising cellulose hydroxypropyl ether;(b) between about 1 mEq and about 160 mEq of antacid comprising sodium bicarbonate; and(c) at least one flavoring agent; wherein the pharmaceutical composition is not enteric coated and has less than 5% total new impurities after 1 year of storage at room temperature;wherein upon administration of the chewable tablet to a fasted subject, the maximum serum concentration of the omeprazole is reached within about 45 minutes after administration. 26. The chewable tablet according to claim 25, wherein the flavoring agent comprises peach, menthol, aspartame, sucralose, sucrose, xylitol, mint, or a mixture thereof. 27. The chewable tablet according to claim 25, wherein a serum concentration of the omeprazole is about 0.5 μg/ml within about 1 hour after administration of the pharmaceutical formulation to a subject. 28. The chewable tablet according to claim 25, wherein about 70% of the omeprazole is released from the composition within about 1.5 hours after exposure to gastrointestinal fluid. 29. The chewable tablet according to claim 25, wherein the antacid is present in an amount of about 1.0 mEq to about 3 mEq per mg of omeprazole. 30. The chewable tablet according to claim 25, wherein the antacid comprises sodium bicarbonate, sodium carbonate, calcium carbonate, magnesium oxide, potassium bicarbonate, magnesium hydroxide, magnesium, carbonate, and mixtures thereof. 31. The chewable tablet according to claim 25, wherein the drug loading of the proton pump inhibitor into microspheres is about 20 wt-% of omeprazole to microencapsulated omeprazole. 32. The chewable tablet according to claim 25, wherein the drug loading of the omeprazole into microspheres is between about 10 wt-% to about 60 wt-% of omeprazole to microencapsulated omeprazole.
Whittle Robert R. ; Sancilio Frederick D. ; Stowell Grayson Walker ; Jenkins Douglas John ; Whittall Linda B., Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same.
Robert R. Whittle ; Frederick D. Sancilio ; Grayson Walker Stowell ; Douglas John Jenkins ; Linda B. Whittall, Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same.
Spickett Robert G. W. (Barcelona ESX) Vidal Jose L. F. (Barcelona ESX) Escoi Juan C. (Barcelona ESX), Antacid compositions with prolonged gastric residence time.
Alminger Tomas B. (Lindome SEX) Bergman Rolf A. (Molndal SEX) Bundgaard H. (Horsholm DKX) Lindberg Per L. (Askim SEX) Sunden Gunnel E. (Gothenburg SEX), Certain pyridyl[(methylthio- or methyl sulfinyl)-2 benzimidazol-2-yl]N-methyl phosphonates useful for treating gastric-a.
Fain Gordon L. (Los Angeles CA) Lee David A. (Los Angeles CA) Lindberg Per L. (Askim CA SEX) Sachs George (Cure Wadsworth CA), Compounds including omeprazole in the treatment of glaucoma.
Briving Carin B. (Billdal SEX) Carlsson Stig A. I. (Mlnlycke SEX) Lindberg Per L. (Askim SEX) Mattsson Annie H. (Askim SEX) Nordberg Mats P. (Gothenburg SEX) Wallmark Bjrn M. G. (Mlnlycke SEX), Derivatives of benzimidazoles active as anti-ulcer agents.
Lindberg Per L. (Askim SEX) Sundn Gunnel E. (Gteborg SEX), Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use.
Whittle Robert R. ; Sancilio Frederick D. ; Stowell Grayson Walker ; Jenkins Douglas John ; Whittall Linda B. ; Fontana Steven A., Dry blend pharmaceutical formulations.
Junggren Ulf K. (Mlnlycke SEX) Sjstrand Sven E. (Kungsbacka SEX), Gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, their preparation, pharmaceutical preparat.
Shell John W. ; Louie-Helm Jenny, Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter.
Gilis Paul Marie Victor,BEX ; Smans Guido Franciscus,BEX ; Gijs Guido Jozef Maria,BEX, Immediate release pH-independent solid dosage form of cisapride.
Upson James G. (Springdale OH) Russell Carmelita M. (Cincinnati OH), Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress.
Zyck, Daniel J.; Sitler, Daniel J.; Barkalow, David G.; Knutsen, Jonathan J.; Shen, Chungsea A.; Zuehlke, Julius W.; Schnell, Philip G., Method for making coated chewing gum products including a high-intensity sweetener.
Min Dong S. (Seoul KRX) Um Kee A. (Suwon KRX) Kim Yong S. (Suwon KRX) Park Pyong W. (Seoul KRX), Method for preparing enteric-coated oral drugs containing acid-unstable compounds.
Lindberg Per,SEX ; Weidolf Lars,SEX, Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazol.
Brndstrm Arne E. (Gothenburg SEX), Method of synthesis of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl-1H-benzimidazole (omeprazole).
Makino Tadashi (Osaka JPX) Tabata Tetsuro (Osaka JPX) Hirai Shin-Ichiro (Kyoto JPX), Method to stabilize a pharmaceutical composition and its production.
Catrenich Carl E. (Fairfield OH) Nelson Dennis G. A. (West Chester OH), Methods and compositions of diphenyl ether phosphate esters for the treatment of gastrointestinal disorders.
Talton,James D.; Hochhaus,Guenther; Singh,Rajiv K.; Fitz Gerald,James M., Methods for preparing coated drug particles and pharmaceutical formulations thereof.
Gary G. Liversidge ; W. Mark Eickhoff ; Kathleen J. Illig ; Pramod Sarpotdar ; Stephen B. Ruddy, Methods for targeting drug delivery to the upper and/or lower gastrointestinal tract.
Brndstrm Arne E. (Gteborg SEX) Carlsson Stig A. I. (Mlnlycke SEX) Kllsson Britt I. M. (Mlndal SEX) Lindberg Per L. (Askim SEX), Novel pharmacologically active compound pyridyl methylsulfinyl benzimidazole.
Kanamaru Tsuneo,JPX ; Nakao Masafumi,JPX ; Tawada Hiroyuki,JPX ; Kamiyama Keiji,JPX, Oxazolone derivatives and their use as anti-Helicobacter pylori agent.
Whittle Robert R. ; Sancilio Frederick D. ; Stowell Grayson Walker ; Jenkins Douglas John ; Whittall Linda B. ; Fontana Steven A., Pharmaceutical unit dosage form.
Cherukuri Subraman R. ; Fuisz Richard C. ; Sanghvi Pradeepkumar P. ; Misra Tushar K. ; Sisak John R., Process for forming chewable quickly dispersing comestible unit and product therefrom.
Fuisz Richard C. ; Cherukuri Subraman R. ; Kota Suresh B. ; Stewart James L., Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom.
Larsson Magnus Erik,SEX ; Stenhede Urban Jan,SEX ; Sorensen Henrik,SEX ; von Unge Sverker Per Oskar,SEX ; Cotton Hanna Kristina,SEX, Process for synthesis of substituted sulphoxides.
Hogberg Jan-.ANG.ke,SEX ; Ioannidis Panagiotis,SEX ; Mattson Anders,SEX, Process for the preparation of a magnesium salt of a substituted sulfinyl heterocycle.
Hoerrner Robert S. (Scotch Plains NJ) Friedman Joel J. (East Brunswick NJ) Amato Joseph S. (Brooklyn NY) Liu Thomas M. (Westfield NJ) Shinkai Ichiro (Westfield NJ) Weinstock Leonard M. (Hilton Head S, Process for the preparation of antiulcer agents.
Debregeas Patrice (Versailles FRX) Leduc Grard (Malesherbes FRX), Stable compositions of gastroprotected omerprazole microgranules and process for the production thereof.
Eek Arne T. (Trosa SEX) Sjostrand Sven E. (Sodertalje SEX), Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic.
Eek Arne T. (Trosa SEX) Sjostrand Sven Erik (Sodertalje SEX), Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic.
Eek Arne T. (Trosa SEX) Sjostrand Sven Erik (Sodertalje SEX), Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic.
Brndstrm Arne E. (Gteborg SEX) Lindberg Per L. (Askim SEX) Starke Carl I. (Gteborg SEX) Sundn Gunnel E. (Gteborg SEX), Therapeutically active chloro substituted benzimidazole.
Brndstrm Arne E. (Gteborg SEX) Lindberg Per L. (Askim SEX) Sunden Gunnel E. (Gteborg SEX), Therapeutically active compound and a process for its preparation.
Johnstone Scott Bowen ; Jones Brad Allen ; Mellon Mark ; Rigby William Roger, Unit dose packaging system (UDPS) having a child resistant locking feature.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.